- Home
- TROO vs MGNX Comparison
TROO vs MGNX Comparison
Compare TROO & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROO
- MGNX
- Stock Information
- Founded
- TROO 2005
- MGNX 2000
- Country
- TROO Hong Kong
- MGNX United States
- Employees
- TROO N/A
- MGNX N/A
- Industry
- TROO Radio And Television Broadcasting And Communications Equipment
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- TROO Technology
- MGNX Health Care
- Exchange
- TROO Nasdaq
- MGNX Nasdaq
- Market Cap
- TROO 215.4M
- MGNX 224.9M
- IPO Year
- TROO N/A
- MGNX 2013
- Fundamental
- Price
- TROO $2.12
- MGNX $4.35
- Analyst Decision
- TROO
- MGNX Buy
- Analyst Count
- TROO 0
- MGNX 11
- Target Price
- TROO N/A
- MGNX $8.57
- AVG Volume (30 Days)
- TROO 4.9K
- MGNX 711.9K
- Earning Date
- TROO 11-19-2024
- MGNX 11-05-2024
- Dividend Yield
- TROO N/A
- MGNX N/A
- EPS Growth
- TROO N/A
- MGNX N/A
- EPS
- TROO N/A
- MGNX N/A
- Revenue
- TROO $3,569,000.00
- MGNX $141,329,000.00
- Revenue This Year
- TROO N/A
- MGNX $110.15
- Revenue Next Year
- TROO N/A
- MGNX N/A
- P/E Ratio
- TROO N/A
- MGNX N/A
- Revenue Growth
- TROO N/A
- MGNX 16.68
- 52 Week Low
- TROO $0.73
- MGNX $2.95
- 52 Week High
- TROO $4.89
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- TROO 37.57
- MGNX 63.27
- Support Level
- TROO $2.20
- MGNX $3.61
- Resistance Level
- TROO $2.29
- MGNX $5.10
- Average True Range (ATR)
- TROO 0.15
- MGNX 0.36
- MACD
- TROO 0.04
- MGNX 0.07
- Stochastic Oscillator
- TROO 14.99
- MGNX 60.30
About TROO TROOPS Inc.
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).